{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T22:09:19Z","timestamp":1782252559941,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,12,25]],"date-time":"2014-12-25T00:00:00Z","timestamp":1419465600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s12185-014-1726-4","type":"journal-article","created":{"date-parts":[[2014,12,24]],"date-time":"2014-12-24T05:52:16Z","timestamp":1419400336000},"page":"173-183","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Improved prediction of clinical outcome in chronic myeloid leukemia"],"prefix":"10.1007","volume":"101","author":[{"given":"Irena","family":"\u0106ojba\u0161i\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana","family":"Ma\u010dukanovi\u0107-Golubovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragan","family":"Mihailovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miodrag","family":"Vu\u010di\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stevo","family":"Luki\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,25]]},"reference":[{"key":"1726_CR1","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1056\/NEJMct071828","volume":"357","author":"C Shiffer","year":"2007","unstructured":"Shiffer C. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med. 2007;357:258\u201365.","journal-title":"N Engl J Med"},{"key":"1726_CR2","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"J Druker","year":"2006","unstructured":"Druker J, Guilhot F, O\u2019Brien S, Gathamann I, Kantarjian HM, Gatterman N, et al. Fife-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408\u201317.","journal-title":"N Engl J Med"},{"key":"1726_CR3","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","volume":"26","author":"H Lavallade de","year":"2008","unstructured":"de Lavallade H, Apperley JF, Khorashad JS, Milojkovi\u0107 D, Reid A, Bua M, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention to treat analysis. J Clin Oncol. 2008;26:3358\u201363.","journal-title":"J Clin Oncol"},{"key":"1726_CR4","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","volume":"103","author":"H Kantarjian","year":"2004","unstructured":"Kantarjian H, Talpaz M, O\u2019Brien S, Garcia-Manero G, Verstovsek S, Giles F, et al. High dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004;103:2873\u20138.","journal-title":"Blood"},{"key":"1726_CR5","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260\u201370.","journal-title":"N Engl J Med"},{"key":"1726_CR6","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","volume":"12","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12:841\u201351.","journal-title":"Lancet Oncol"},{"key":"1726_CR7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/cas.12321","volume":"105","author":"E Yamamoto","year":"2014","unstructured":"Yamamoto E, Fujisawa S, Hagihara M, Tanaka M, Fujimaki K, Kishimoto K, et al. European treatment and outcome study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients. Cancer Sci. 2014;105:105\u20139.","journal-title":"Cancer Sci"},{"issue":"4","key":"1726_CR8","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in \u201cgood risk\u201d chronic granulocytic leukemia. Blood. 1984;63(4):789\u201399.","journal-title":"Blood"},{"key":"1726_CR9","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","volume":"90","author":"J Hasford","year":"1998","unstructured":"Hasford J, Pfirmann M, Hehlmann R, Alann NC, Baccarani M, Kluin-Nelemans JC, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst. 1998;90:850\u20138.","journal-title":"J Natl Cancer Inst"},{"key":"1726_CR10","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","volume":"118","author":"J Hasford","year":"2011","unstructured":"Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011;118:686\u201392.","journal-title":"Blood"},{"key":"1726_CR11","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1200\/JCO.2011.37.6962","volume":"29","author":"D Marin","year":"2011","unstructured":"Marin D, Ibrahim AR, Goldman JM. European treatment and out come study (EUTOS) score for chronic myeloid leukemia still require more confirmation. J Clin Oncol. 2011;29:3944\u20135.","journal-title":"J Clin Oncol"},{"key":"1726_CR12","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1182\/blood-2011-10-388967","volume":"119","author":"E Jabbour","year":"2012","unstructured":"Jabbour E, Cortes J, Nazha A, O\u2019Brien S, Quintas-Cardama A, Pierce S, et al. EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. Blood. 2012;119:4524\u20136.","journal-title":"Blood"},{"key":"1726_CR13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/sj.leu.2402769","volume":"17","author":"P Korkolopoulou","year":"2003","unstructured":"Korkolopoulou P, Viniou N, Kavantzas N, Patsouris E, Thymara I, Pavlopoulos PM, et al. Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid leukemia: a morphometric study. Leukemia. 2003;17:89\u201397.","journal-title":"Leukemia"},{"key":"1726_CR14","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane FD, Niederwieser D, Saglio D, Apperley J, et al. Chronic myeloid leukemia. An update of concepts and management recommendations of the European LeukemiaNet. J Clin Oncol. 2009;27:6041\u201351.","journal-title":"J Clin Oncol"},{"key":"1726_CR15","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872\u201384.","journal-title":"Blood"},{"key":"1726_CR16","first-page":"77","volume":"29","author":"SM Hsu","year":"1981","unstructured":"Hsu SM, Raine L, Fanger L. User of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabelled antibody (PAP) procedures. J Hisohem Cytochem. 1981;29:77\u201380.","journal-title":"J Hisohem Cytochem"},{"issue":"8","key":"1726_CR17","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/blood.V95.8.2637","volume":"95","author":"T Padr\u00f3","year":"2000","unstructured":"Padr\u00f3 T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood. 2000;95(8):2637\u201344.","journal-title":"Blood"},{"key":"1726_CR18","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/S0959-8049(96)00379-6","volume":"32","author":"PB Vermeulan","year":"1996","unstructured":"Vermeulan PB, Gasparini G, Fox SB, Toj M, Martin L, McCulloch P, et al. Quantification of angiogenesis in solid human tumorous; an international consensus on the methodology and criteria of evaluation. Eur J Cancer. 1996;32:2474\u201384.","journal-title":"Eur J Cancer"},{"key":"1726_CR19","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/00401706.1962.10490038","volume":"4","author":"GE Box","year":"1962","unstructured":"Box GE, Tidwell PW. Transformation of the independent variables. Technometrics. 1962;4:531\u201350.","journal-title":"Technometrics"},{"key":"1726_CR20","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1214\/aos\/1176345513","volume":"9","author":"D Pregibon","year":"1981","unstructured":"Pregibon D. Logistic regression diagnostics. Ann Stat. 1981;9:705\u201324.","journal-title":"Ann Stat"},{"key":"1726_CR21","doi-asserted-by":"crossref","DOI":"10.1002\/0471722146","volume-title":"Applied logistic regression","author":"DW Hosmer","year":"2000","unstructured":"Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley; 2000."},{"key":"1726_CR22","doi-asserted-by":"crossref","unstructured":"Kleinbaum DG, Klein M. Logistic regression: a self-learning text 3rd edition, Springer Science Business Media LLC, 2010.","DOI":"10.1007\/978-1-4419-1742-3"},{"key":"1726_CR23","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1148\/radiology.148.3.6878708","volume":"148","author":"J Hanley","year":"1983","unstructured":"Hanley J, McNeil B. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148:839\u201343.","journal-title":"Radiology"},{"key":"1726_CR24","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4899-4541-9","volume-title":"An introduction to the bootstrap","author":"B Efron","year":"1993","unstructured":"Efron B, Tibshirani R. An introduction to the bootstrap. London: Chapman and Hall; 1993."},{"key":"1726_CR25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0002-9440(10)64511-7","volume":"157","author":"LG Lundberg","year":"2000","unstructured":"Lundberg LG, Lerner R, Sundelin P, Rogers R, Folkman J, Palmblad J. Bone marrow in polycythemia vera, chronic myelocytic leukemia and myelofibrosis has an increased vascularity. Am J Pathol. 2000;157:15\u20139.","journal-title":"Am J Pathol"},{"key":"1726_CR26","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood.V96.6.2240","volume":"96","author":"A Aguayo","year":"2000","unstructured":"Aguayo A, Kantarjian HM, Manshouri T, Gidel C, Estey E, Thomas D, et al. Angigenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000;96:2240\u20135.","journal-title":"Blood"},{"key":"1726_CR27","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s12185-012-1043-8","volume":"95","author":"P Trask","year":"2012","unstructured":"Trask P, Mitra D, Iyer S, Candrilli S, Kaye J. Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study. Int J Hematol. 2012;95:535\u201344.","journal-title":"Int J Hematol"},{"key":"1726_CR28","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/blood-2002-09-2790","volume":"101","author":"JE Cortes","year":"2003","unstructured":"Cortes JE, Talpaz M, Giles F, O\u2019Brien S, Rios MB, Shan J, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 2003;101:3794\u2013800.","journal-title":"Blood"},{"key":"1726_CR29","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/cncr.25015","volume":"116","author":"D Verma","year":"2010","unstructured":"Verma D, Kantarjian H, Shan J, O\u2019Brien S, Estrov Z, Garcia-Manero G, et al. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer. 2010;116:2673\u201381.","journal-title":"Cancer"},{"key":"1726_CR30","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3109\/02841861003660031","volume":"49","author":"F Stagno","year":"2010","unstructured":"Stagno F, Vigneri P, Del Fabro V, Stella S, Cupri A, Massimino M, et al. Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Acta Oncol. 2010;49:506\u20138.","journal-title":"Acta Oncol"},{"key":"1726_CR31","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3324\/haematol.2009.009134","volume":"94","author":"CM Lucas","year":"2009","unstructured":"Lucas CM, Harris RJ, Giannoudis A, Davies A, Knight K, Watmough SJ, et al. Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. Haematologica. 2009;94:1362\u20137.","journal-title":"Haematologica"},{"key":"1726_CR32","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2009.26.5819","volume":"28","author":"DL White","year":"2010","unstructured":"White DL, Dang P, Engler J, Frede A, Zrim S, Osborn M, et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol. 2010;28:2761\u20137.","journal-title":"J Clin Oncol"},{"key":"1726_CR33","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1001\/jama.1997.03540300056034","volume":"277","author":"A Laupacis","year":"1997","unstructured":"Laupacis A, Sekar N, Stiell IG. Clinical prediction rules: a review and suggested modifications of methodological standards. JAMA. 1997;277:488\u201394.","journal-title":"JAMA"},{"key":"1726_CR34","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/archinte.165.2.138","volume":"165","author":"DJ Brotman","year":"2005","unstructured":"Brotman DJ, Walker E, Lauer MS, O\u2019Brien RG. In search of fewer independent risk factors. Arch Intern Med. 2005;165:138\u201345.","journal-title":"Arch Intern Med"},{"key":"1726_CR35","doi-asserted-by":"crossref","first-page":"b375","DOI":"10.1136\/bmj.b375","volume":"338","author":"KG Moons","year":"2009","unstructured":"Moons KG, Royston P, Vergouwe Y, Grobbee DE, Altman DG. Prognosis and prognostic research: what, why and how? BMJ. 2009;338:b375.","journal-title":"BMJ"},{"issue":"307","key":"1726_CR36","first-page":"199","volume":"11","author":"TM Gil","year":"2012","unstructured":"Gil TM. The central role of prognosis in clinical decision making. JAMA. 2012;11(307):199\u2013200.","journal-title":"JAMA"},{"key":"1726_CR37","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-77244-8","volume-title":"Clinical prediction models: a practical approach to development, validation, and updating","author":"E Steyerberg","year":"2009","unstructured":"Steyerberg E. Clinical prediction models: a practical approach to development, validation, and updating. New York: Springer Science Business Media; 2009."},{"key":"1726_CR38","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1093\/annonc\/mds341","volume":"24","author":"B Gwilliam","year":"2012","unstructured":"Gwilliam B, Keeley V, Todd C, Roberts C, Gittins M, Kelly L, et al. Prognosticating in patients with advanced cancer-observational study comparing the accuracy of clinicians \u2018and patients\u2019 estimates of survival. Ann Oncol. 2012;24:482\u20138.","journal-title":"Ann Oncol"},{"key":"1726_CR39","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.earlhumdev.2012.01.001","volume":"88","author":"S Luki\u0107","year":"2012","unstructured":"Luki\u0107 S, \u0106ojba\u0161i\u0107 \u017d, Jovi\u0107 N, Popovi\u0107 M, Bjelakovi\u0107 B, Dimitrijevi\u0107 L, Bjelakovi\u0107 Lj. Artificial neural networks based prediction of cerebral palsy in infants with central coordination disturbance. Early Human Dev. 2012;88:547\u201353.","journal-title":"Early Human Dev"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-014-1726-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-014-1726-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-014-1726-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T03:47:01Z","timestamp":1717645621000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-014-1726-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,25]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["1726"],"URL":"https:\/\/doi.org\/10.1007\/s12185-014-1726-4","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,25]]}}}